All In Biotech

Drug Trial Radar · NCT05119569

A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 109 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

109

Actual

Start

Mar 1, 2022

Primary completion

Mar 29, 2023

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Nov 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study evaluating the effect of fenebrutinib on brain magnetic resonance imaging (MRI) in participants with RMS. The safety and pharmacokinetics of fenebrutinib will also be evaluated. Participants will be randomized to receive either fenebrutinib or placebo. This study consists of two parts: Double-blind treatment (DBT) phase and an optional Open-label extension (OLE) phase.

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • FenebrutinibDrug

    Fenebrutinib will be administered orally.

  • PlaceboDrug

    Placebo will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DBT Phase: New Gadolinium (Gd) - Enhancing T1 Lesion Rate Observed on Magnetic Resonance Imaging (MRI) Scans of the Brain Over 12 WeeksTime frame: MRI scans performed at Weeks 4, 8 and 12

Locations

17 sites in 6 countries. Site status is shown where the registry gives one.

  • Fullerton Neurology and Headache Center

    Fullerton, California

  • Cleveland Clinic Lou Ruvo

    Las Vegas, Nevada

  • University Clinical Centre of the Republic of Srpska

    Banja Luka, Bosnia and Herzegovina

  • Clinical Hospital Center Rijeka - PPDS

    Rijeka, Croatia

  • General Hospital Varazdin

    Varaždin, Croatia

  • Klinicki bolnicki centar Zagreb

    Zagreb, Croatia

  • Poliklinika Solmed

    Zagreb, Croatia

  • Fakultni nemocnice u sv. Anny v Brne

    Brno, Czechia

  • Fakultni nemocnice Hradec Kralove

    Hradec Králové, Czechia

  • Vseobecna Fakultni Nemocnice V Praze - CRC - PPDS

    Prague, Czechia

  • Nemocnice Jihlava, prispevkova organizace

    Jihlava, Vyso?ina, Czechia

  • Clinical Center of Serbia

    Belgrade, Serbia

  • Military Medical Academy

    Belgrade, Serbia

  • Clinical center Kragujevac

    Kragujevac, Serbia

  • Clinical Center Nis

    Niš, Serbia

  • Clinical Hospital Centre Zemun

    Zemun, Serbia

  • Univerzitna nemocnica Bratislava

    Bratislava, Slovakia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.